Journal article
Survival with Tiotropium Compared to Long-Acting Beta-2-Agonists in Chronic Obstructive Pulmonary Disease
Abstract
Chronic Obstructive Pulmonary Disease (COPD) is the fourth-leading cause of chronic morbidity and mortality in North America and its burden continues to increase. Tiotropium has been shown to reduce exacerbations, hospitalizations, symptoms, and improve health-related quality of life in patients with COPD. Its effect on mortality and its effects relative to long-acting beta-agonists (LABAs), however, remain unknown. To examine the association …
Authors
Gershon AS; Wang L; To T; Luo J; Upshur REG
Journal
COPD Journal of Chronic Obstructive Pulmonary Disease, Vol. 5, No. 4, pp. 229–234
Publisher
Taylor & Francis
Publication Date
1 2008
DOI
10.1080/15412550802237507
ISSN
1541-2555
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
Administration, InhalationAdrenergic beta-AgonistsAge DistributionAgedAged, 80 and overBronchodilator AgentsCause of DeathCohort StudiesContinuity of Patient CareDelayed-Action PreparationsDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHumansKaplan-Meier EstimateLongitudinal StudiesMaleOntarioPrognosisProportional Hazards ModelsPulmonary Disease, Chronic ObstructiveRegistriesRespiratory Function TestsRisk AssessmentScopolamine DerivativesSeverity of Illness IndexSex DistributionSurvival AnalysisTiotropium BromideTreatment Outcome